Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
Looking At DepoMed's Serada For Hot FlashesJason Napodano • Wed, Oct 3, 2012
-
-
-
-
-
-
-
-
-
What Gralise Approval Means for DepomedM. E. Garza • Mon, Jan 31, 2011 -
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
3 Liquid Small Cap Healthcare Stocks Set For GrowthZetaKap • Thu, Sep 20, 2012 -
-
-
-
-
-
-
-
-
3 Small-Cap Stocks Undervalued By The Graham NumberKapitall • Tue, Mar 13, 2012
-
Hedge Funds Love These 4 Highly Undervalued Healthcare StocksKapitall • Fri, Mar 2, 2012
-
-
-
-
DepoMed's CEO Discusses Q3 2012 Results - Earnings Call TranscriptMon, Nov 5, 2012
-
Depomed, Inc. Q1 2010 Earnings Call TranscriptMon, May 3, 2010
-
DepoMed, Inc. Q2 2009 Earnings Call TranscriptThu, Jul 30, 2009
-
DepoMed, Inc., Q1 2009 Earnings Call TranscriptMon, May 4, 2009
-
DepoMed, Inc. Q4 2008 Earnings Call TranscriptThu, Mar 5, 2009
-
Depomed, Inc. Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Depomed, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 25, 2008
-
Depomed Inc. Q4 2007 Earnings Call TranscriptThu, Mar 6, 2008
-
PR Newswire (Jun 11, 2013)
-
PR Newswire (May 31, 2013)
-
PR Newswire (May 28, 2013)
-
PR Newswire (May 16, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Feb 26, 2013)
-
PR Newswire (Feb 20, 2013)
-
PR Newswire (Feb 13, 2013)
-
PR Newswire (Dec 3, 2012)
-
PR Newswire (Nov 19, 2012)
-
PR Newswire (Nov 7, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Nov 5, 2012)
-
PR Newswire (Oct 29, 2012)
DEPO vs. ETF Alternatives
Company Description
Depomed is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that address large and growing markets and are based on proprietary oral drug delivery technologies. In 2009, we completed Phase 3 clinical trials for two product... More
